Skip to Content

Find Comparable Stocks for Merck & Co., Inc.

Merck & Co., Inc.

MRK - NYQ
Life Sciences
Pharmaceutical Preparations
Country
USA
Market Cap
$236.1B
Dividend Yield
4%
Beta
0.36 (No Correlation)
Trading Volume
6.2M (Moderate)
Momentum
Very Weak Weak Very Strong
Value vs. Growth
Deep Value Fair Value Rapid Growth
Quality
Poor Good Excellent
Size
Micro Mega Cap Mega Cap

Merck & Co. is an American multinational pharmaceutical company headquartered in Kenilworth, New Jersey. It is named after the Merck family, which set up Merck Group in Germany in 1668.

Valuation
Financials
Momentum
Analyst Ratings
Trailing P/E
13.83
Forward P/E
10.28
PEG Ratio
0.85
Price/Book
5.05
EV/EBITDA
10.01
EV/Revenue
4.01

Income Statement

Revenue (TTM)
$64.2B
Gross Profit (TTM)
$49.5B
EBITDA
$29.1B

Financial Ratios

Profit Margin
27%
Operating Margin (TTM)
34%
Gross Profit Margin
77%
EBITDA Margin
45%
ROE (TTM)
41%
ROA (TTM)
14%

Growth

Quarterly Revenue Growth (YoY)
7%
Quarterly Earnings Growth (YoY)
-33%
52-Week Range
$81.04
$93.48
$132.67
50-Day Moving Average
$94.57
Price vs. 50-Day MA
-1.15%
200-Day Moving Average
$110.10
Price vs. 200-Day MA
-15.10%
Analyst Ratings Distribution
0
0
9
12
5
Strong Sell Strong Buy
Median Price Target
$112.78
Price to Target
83%

Pfizer Inc.

PFE - NYQ
View PFE's Comps
A+
TaxGhost's "TG Grade" is calculated from 100+ datapoints including fundamental metrics, factors, country, correlation, sub-sector, and more.
Life Sciences
Pharmaceutical Preparations
Market Cap: $146.6B
Volume: 24.6M (High)
Beta: 0.54 (Low)
Dividend Yield: 7%
Weak Momentum
Value
Average Quality
Large Cap

Pfizer Inc. is an American multinational pharmaceutical and biotechnology corporation headquartered on 42nd Street in Manhattan, New York City. The name of the company commemorates its co-founder, Charles Pfizer (1824-1906). Pfizer develops and produces medicines and vaccines for immunology, oncology, cardiology, endocrinology, and neurology. The company has several blockbuster drugs or products that each generate more than 1 billion USD in annual revenues.

Compare
Valuation
Financials
Momentum
Ratings

Pfizer Inc. is a key competitor in the pharmaceutical industry, known for its diverse portfolio of medications and vaccines, making it a direct peer to Merck in the life sciences sector.

correlation
B+

correlation

Measures how closely the two stocks' prices move together over time. A high correlation suggests similar market reactions and investor sentiment.

Pearson Correlation: 38%

R-squared: 14%

This indicates a weak positive relationship between the price movements of these stocks.

network
A+

network

Evaluates the overlap in business networks, partnerships, and industry relationships, indicating similarity in market positioning and competitive landscape.

  • Common comparables: 5
  • MRK in PFE's comparables: Yes
  • PFE in MRK's comparables: Yes

A high score suggests the companies are often compared to each other and share many industry peers, indicating similar competitive environments and market perceptions.

financials
A-

financials

Compares key financial metrics to assess operational similarity and financial health.

  • Revenue Growth: 7% vs 22%
  • Profit Margin: 27% vs 13%
  • ROE: 41% vs 9%
  • Operating Margin: 34% vs 16%
  • Revenue (TTM): $64.2B vs $63.6B

A high score indicates similar financial performance, efficiency, and growth trajectories, suggesting comparable business models and market positions.

size
A+

size

Evaluates similarity in market capitalization, which can indicate comparable market influence, investor interest, and resource availability.

Market Cap: $236.1B vs $146.6B

Size Category: Mega Cap vs Large Cap

A high score suggests the companies are in the same size category, facing similar challenges and opportunities in terms of market presence and financial flexibility.

valuation
A+

valuation

Compares valuation metrics to assess if the stocks are valued similarly by the market, indicating comparable investor expectations and perceived growth potential.

  • P/E Ratio: 13.87 vs 18.35
  • P/B Ratio: 5.05 vs 1.69
  • EV/EBITDA: 10.01 vs 10.59
  • Forward P/E: 10.28 vs 8.87
  • PEG Ratio: 0.85 vs 0.18

A high score indicates that the market values these companies similarly relative to their financials, suggesting comparable growth expectations and risk profiles.

sector
A+

sector

Compares the sector and industry classification of both companies, allowing for partial matches.

  • Sector: LIFE SCIENCES vs LIFE SCIENCES
  • Industry: PHARMACEUTICAL PREPARATIONS vs PHARMACEUTICAL PREPARATIONS

A high score indicates that the companies operate in similar business areas, facing comparable market conditions, regulatory environments, and industry trends. Partial matches are considered for more nuanced comparisons.

analyst ratings
A+

analyst ratings

Compares the consensus of analyst opinions on both stocks.

  • MRK Rating: Buy
  • PFE Rating: Hold

A high score suggests that analysts view both stocks similarly in terms of their future prospects and investment potential.

geo
A+

geo

Evaluates the geographical similarity of the companies based on country, currency, exchange, and address.

  • MRK Country: USA
  • PFE Country: USA
  • Currency: USD vs USD
  • Exchange: NYQ vs NYQ

A high score indicates that both companies operate in similar geographical markets, facing comparable economic conditions, regulations, and market dynamics.

volatility
A

volatility

Compares price volatility and risk profiles, indicating similarity in market behavior, risk, and potential for price swings.

  • MRK Beta: 0.36 (No Correlation)
  • PFE Beta: 0.54 (Low)

A high score suggests both stocks have similar sensitivity to market movements, implying comparable risk levels and potential for both gains and losses.

business similarity
A+

business similarity

Assesses the similarity of the companies' business models, products, and services.

This score is based on an analysis of the companies' business descriptions, major products, and revenue streams.

A high score indicates that the companies have similar core businesses, target markets, and revenue generation strategies.

momentum
A+

momentum

Compares recent price momentum, showing similarity in short-term market performance and investor sentiment.

  • MRK Price vs 200-day MA: 84.90%
  • PFE Price vs 200-day MA: 93.09%

A high score indicates both stocks are experiencing similar price trends relative to their recent history, suggesting comparable market enthusiasm or concern.

dividend
B+

dividend

Compares dividend policies, showing similarity in shareholder return strategies and income potential for investors.

  • MRK Dividend Yield: 4%
  • PFE Dividend Yield: 7%

A high score indicates similar approaches to returning capital to shareholders, suggesting comparable appeal to income-focused investors.

Select Mutual Comparables:

Trailing P/E
18.66
Forward P/E
8.87
PEG Ratio
0.18
Price/Book
1.69
EV/EBITDA
10.59
EV/Revenue
3.02

Income Statement

Revenue (TTM)
$63.6B
Gross Profit (TTM)
$47.2B
EBITDA
$23.3B

Financial Ratios

Profit Margin
13%
Operating Margin (TTM)
16%
Gross Profit Margin
N/A
EBITDA Margin
N/A
ROE (TTM)
9%
ROA (TTM)
5%

Growth

Quarterly Revenue Growth (YoY)
22%
Quarterly Earnings Growth (YoY)
-98%
52-Week Range
$23.71
$25.87
$30.55
50-Day Moving Average
$26.31
Price vs. 50-Day MA
-1.67%
200-Day Moving Average
$27.79
Price vs. 200-Day MA
-6.91%
Analyst Ratings Distribution
0
1
13
6
3
Strong Sell Strong Buy
Median Price Target
$31.09
Price to Target
83%

Johnson & Johnson

JNJ - NYQ
View JNJ's Comps
A+
TaxGhost's "TG Grade" is calculated from 100+ datapoints including fundamental metrics, factors, country, correlation, sub-sector, and more.
Life Sciences
Pharmaceutical Preparations
Market Cap: $397.3B
Volume: 12.0M (High)
Beta: 0.51 (Low)
Dividend Yield: 3%
Neutral Momentum
Fair Value
Average Quality
Mega Cap

Johnson & Johnson (J&J) is an American multinational corporation founded in 1886 that develops medical devices, pharmaceuticals, and consumer packaged goods. Its common stock is a component of the Dow Jones Industrial Average and the company is ranked No. 36 on the 2021 Fortune 500 list of the largest United States corporations by total revenue. Johnson & Johnson is one of the world's most valuable companies, and is one of only two U.S.-based companies that has a prime credit rating of AAA, higher than that of the United States government.

Compare
Valuation
Financials
Momentum
Ratings

Merck & Co. is a global healthcare company with a strong pharmaceutical portfolio, making it a direct competitor to J&J in the pharmaceutical preparations industry.

correlation
B+

correlation

Measures how closely the two stocks' prices move together over time. A high correlation suggests similar market reactions and investor sentiment.

Pearson Correlation: 33%

R-squared: 11%

This indicates a weak positive relationship between the price movements of these stocks.

network
A+

network

Evaluates the overlap in business networks, partnerships, and industry relationships, indicating similarity in market positioning and competitive landscape.

  • Common comparables: 6
  • JNJ in MRK's comparables: Yes
  • MRK in JNJ's comparables: Yes

A high score suggests the companies are often compared to each other and share many industry peers, indicating similar competitive environments and market perceptions.

financials
A

financials

Compares key financial metrics to assess operational similarity and financial health.

  • Revenue Growth: 5% vs 7%
  • Profit Margin: 16% vs 27%
  • ROE: 20% vs 41%
  • Operating Margin: 18% vs 34%
  • Revenue (TTM): $88.8B vs $64.2B

A high score indicates similar financial performance, efficiency, and growth trajectories, suggesting comparable business models and market positions.

size
A+

size

Evaluates similarity in market capitalization, which can indicate comparable market influence, investor interest, and resource availability.

Market Cap: $397.3B vs $236.1B

Size Category: Mega Cap vs Mega Cap

A high score suggests the companies are in the same size category, facing similar challenges and opportunities in terms of market presence and financial flexibility.

valuation
A+

valuation

Compares valuation metrics to assess if the stocks are valued similarly by the market, indicating comparable investor expectations and perceived growth potential.

  • P/E Ratio: 28.50 vs 13.87
  • P/B Ratio: 5.56 vs 5.05
  • EV/EBITDA: 16.52 vs 10.01
  • Forward P/E: 15.58 vs 10.28
  • PEG Ratio: 1.12 vs 0.85

A high score indicates that the market values these companies similarly relative to their financials, suggesting comparable growth expectations and risk profiles.

sector
A+

sector

Compares the sector and industry classification of both companies, allowing for partial matches.

  • Sector: LIFE SCIENCES vs LIFE SCIENCES
  • Industry: PHARMACEUTICAL PREPARATIONS vs PHARMACEUTICAL PREPARATIONS

A high score indicates that the companies operate in similar business areas, facing comparable market conditions, regulatory environments, and industry trends. Partial matches are considered for more nuanced comparisons.

analyst ratings
A+

analyst ratings

Compares the consensus of analyst opinions on both stocks.

  • JNJ Rating: Buy
  • MRK Rating: Buy

A high score suggests that analysts view both stocks similarly in terms of their future prospects and investment potential.

geo
A+

geo

Evaluates the geographical similarity of the companies based on country, currency, exchange, and address.

  • JNJ Country: USA
  • MRK Country: USA
  • Currency: USD vs USD
  • Exchange: NYQ vs NYQ

A high score indicates that both companies operate in similar geographical markets, facing comparable economic conditions, regulations, and market dynamics.

volatility
A

volatility

Compares price volatility and risk profiles, indicating similarity in market behavior, risk, and potential for price swings.

  • JNJ Beta: 0.51 (Low)
  • MRK Beta: 0.36 (No Correlation)

A high score suggests both stocks have similar sensitivity to market movements, implying comparable risk levels and potential for both gains and losses.

business similarity
A+

business similarity

Assesses the similarity of the companies' business models, products, and services.

This score is based on an analysis of the companies' business descriptions, major products, and revenue streams.

A high score indicates that the companies have similar core businesses, target markets, and revenue generation strategies.

momentum
A+

momentum

Compares recent price momentum, showing similarity in short-term market performance and investor sentiment.

  • JNJ Price vs 200-day MA: 106.67%
  • MRK Price vs 200-day MA: 84.90%

A high score indicates both stocks are experiencing similar price trends relative to their recent history, suggesting comparable market enthusiasm or concern.

dividend
A+

dividend

Compares dividend policies, showing similarity in shareholder return strategies and income potential for investors.

  • JNJ Dividend Yield: 3%
  • MRK Dividend Yield: 4%

A high score indicates similar approaches to returning capital to shareholders, suggesting comparable appeal to income-focused investors.

Select Mutual Comparables:

Trailing P/E
28.50
Forward P/E
15.58
PEG Ratio
1.12
Price/Book
5.56
EV/EBITDA
16.52
EV/Revenue
4.61

Income Statement

Revenue (TTM)
$88.8B
Gross Profit (TTM)
$61.8B
EBITDA
$29.9B

Financial Ratios

Profit Margin
16%
Operating Margin (TTM)
18%
Gross Profit Margin
N/A
EBITDA Margin
N/A
ROE (TTM)
20%
ROA (TTM)
8%

Growth

Quarterly Revenue Growth (YoY)
5%
Quarterly Earnings Growth (YoY)
-3%
52-Week Range
$138.68
$165.02
$166.43
50-Day Moving Average
$150.65
Price vs. 50-Day MA
9.54%
200-Day Moving Average
$154.70
Price vs. 200-Day MA
6.67%
Analyst Ratings Distribution
0
0
11
7
4
Strong Sell Strong Buy
Median Price Target
$168.44
Price to Target
98%

GSK plc

GSK - NYQ
View GSK's Comps
A
TaxGhost's "TG Grade" is calculated from 100+ datapoints including fundamental metrics, factors, country, correlation, sub-sector, and more.
Life Sciences
Pharmaceutical Preparations
Market Cap: $81.6B
Volume: 8.1M (Moderate)
Beta: 0.29 (No Correlation)
Dividend Yield: 4%
Neutral Momentum
Value
Good Quality
Large Cap

GlaxoSmithKline plc is dedicated to the creation, discovery, development, manufacture and marketing of pharmaceuticals, vaccines, over-the-counter drugs and health-related consumer products in the UK, US and internationally. The company is headquartered in Brentford, the United Kingdom.

Compare
Valuation
Financials
Momentum
Ratings

GlaxoSmithKline plc is a global healthcare company focused on pharmaceuticals and vaccines, paralleling Merck in terms of product offerings and market strategy within the life sciences sector.

correlation
B

correlation

Measures how closely the two stocks' prices move together over time. A high correlation suggests similar market reactions and investor sentiment.

Pearson Correlation: 25%

R-squared: 6%

This indicates a negligible relationship between the price movements of these stocks.

network
A+

network

Evaluates the overlap in business networks, partnerships, and industry relationships, indicating similarity in market positioning and competitive landscape.

  • Common comparables: 6
  • GSK in MRK's comparables: Yes
  • MRK in GSK's comparables: No

A high score suggests the companies are often compared to each other and share many industry peers, indicating similar competitive environments and market perceptions.

financials
B+

financials

Compares key financial metrics to assess operational similarity and financial health.

  • Revenue Growth: 1% vs 7%
  • Profit Margin: 8% vs 27%
  • ROE: 23% vs 41%
  • Operating Margin: 12% vs 34%
  • Revenue (TTM): $31.4B vs $64.2B

A high score indicates similar financial performance, efficiency, and growth trajectories, suggesting comparable business models and market positions.

size
A+

size

Evaluates similarity in market capitalization, which can indicate comparable market influence, investor interest, and resource availability.

Market Cap: $81.6B vs $236.1B

Size Category: Large Cap vs Mega Cap

A high score suggests the companies are in the same size category, facing similar challenges and opportunities in terms of market presence and financial flexibility.

valuation
A+

valuation

Compares valuation metrics to assess if the stocks are valued similarly by the market, indicating comparable investor expectations and perceived growth potential.

  • P/E Ratio: 25.03 vs 13.87
  • P/B Ratio: 4.63 vs 5.05
  • EV/EBITDA: 11.37 vs 10.01
  • Forward P/E: 9.15 vs 10.28
  • PEG Ratio: 0.87 vs 0.85

A high score indicates that the market values these companies similarly relative to their financials, suggesting comparable growth expectations and risk profiles.

sector
A+

sector

Compares the sector and industry classification of both companies, allowing for partial matches.

  • Sector: LIFE SCIENCES vs LIFE SCIENCES
  • Industry: PHARMACEUTICAL PREPARATIONS vs PHARMACEUTICAL PREPARATIONS

A high score indicates that the companies operate in similar business areas, facing comparable market conditions, regulatory environments, and industry trends. Partial matches are considered for more nuanced comparisons.

analyst ratings
A+

analyst ratings

Compares the consensus of analyst opinions on both stocks.

  • GSK Rating: Hold
  • MRK Rating: Buy

A high score suggests that analysts view both stocks similarly in terms of their future prospects and investment potential.

geo
A+

geo

Evaluates the geographical similarity of the companies based on country, currency, exchange, and address.

  • GSK Country: USA
  • MRK Country: USA
  • Currency: USD vs USD
  • Exchange: NYQ vs NYQ

A high score indicates that both companies operate in similar geographical markets, facing comparable economic conditions, regulations, and market dynamics.

volatility
A+

volatility

Compares price volatility and risk profiles, indicating similarity in market behavior, risk, and potential for price swings.

  • GSK Beta: 0.29 (No Correlation)
  • MRK Beta: 0.36 (No Correlation)

A high score suggests both stocks have similar sensitivity to market movements, implying comparable risk levels and potential for both gains and losses.

business similarity
A

business similarity

Assesses the similarity of the companies' business models, products, and services.

This score is based on an analysis of the companies' business descriptions, major products, and revenue streams.

A high score indicates that the companies have similar core businesses, target markets, and revenue generation strategies.

momentum
A+

momentum

Compares recent price momentum, showing similarity in short-term market performance and investor sentiment.

  • GSK Price vs 200-day MA: 104.49%
  • MRK Price vs 200-day MA: 84.90%

A high score indicates both stocks are experiencing similar price trends relative to their recent history, suggesting comparable market enthusiasm or concern.

dividend
A+

dividend

Compares dividend policies, showing similarity in shareholder return strategies and income potential for investors.

  • GSK Dividend Yield: 4%
  • MRK Dividend Yield: 4%

A high score indicates similar approaches to returning capital to shareholders, suggesting comparable appeal to income-focused investors.

Select Mutual Comparables:

Trailing P/E
25.03
Forward P/E
9.15
PEG Ratio
0.87
Price/Book
4.63
EV/EBITDA
11.37
EV/Revenue
2.42

Income Statement

Revenue (TTM)
$31.4B
Gross Profit (TTM)
$22.5B
EBITDA
$8.3B

Financial Ratios

Profit Margin
8%
Operating Margin (TTM)
12%
Gross Profit Margin
N/A
EBITDA Margin
N/A
ROE (TTM)
23%
ROA (TTM)
7%

Growth

Quarterly Revenue Growth (YoY)
1%
Quarterly Earnings Growth (YoY)
17%
52-Week Range
$31.37
$40.05
$44.37
50-Day Moving Average
$35.45
Price vs. 50-Day MA
12.98%
200-Day Moving Average
$38.33
Price vs. 200-Day MA
4.49%
Analyst Ratings Distribution
1
1
3
2
1
Strong Sell Strong Buy
Median Price Target
$43.42
Price to Target
92%

Bristol-Myers Squibb Company

BMY - NYQ
View BMY's Comps
A
TaxGhost's "TG Grade" is calculated from 100+ datapoints including fundamental metrics, factors, country, correlation, sub-sector, and more.
Life Sciences
Pharmaceutical Preparations
Market Cap: $121.4B
Volume: 6.3M (Moderate)
Beta: 0.44 (Low)
Dividend Yield: 4%
Neutral Momentum
Fair Value
Average Quality
Large Cap

Bristol Myers Squibb (BMS) is an American multinational pharmaceutical company, headquartered in New York City. Bristol Myers Squibb manufactures prescription pharmaceuticals and biologics in several therapeutic areas, including cancer, AIDS, cardiovascular disease, diabetes, hepatitis, rheumatoid arthritis and psychiatric disorders.

Compare
Valuation
Financials
Momentum
Ratings

Merck & Co., Inc. is a global healthcare company engaged in pharmaceuticals and vaccines, with a focus on oncology and infectious diseases, which parallels Bristol-Myers Squibb's therapeutic interests.

correlation
B-

correlation

Measures how closely the two stocks' prices move together over time. A high correlation suggests similar market reactions and investor sentiment.

Pearson Correlation: 19%

R-squared: 4%

This indicates a negligible relationship between the price movements of these stocks.

network
A+

network

Evaluates the overlap in business networks, partnerships, and industry relationships, indicating similarity in market positioning and competitive landscape.

  • Common comparables: 5
  • BMY in MRK's comparables: Yes
  • MRK in BMY's comparables: Yes

A high score suggests the companies are often compared to each other and share many industry peers, indicating similar competitive environments and market perceptions.

financials
B

financials

Compares key financial metrics to assess operational similarity and financial health.

  • Revenue Growth: 8% vs 7%
  • Profit Margin: -19% vs 27%
  • ROE: -39% vs 41%
  • Operating Margin: 23% vs 34%
  • Revenue (TTM): $48.3B vs $64.2B

A high score indicates similar financial performance, efficiency, and growth trajectories, suggesting comparable business models and market positions.

size
A+

size

Evaluates similarity in market capitalization, which can indicate comparable market influence, investor interest, and resource availability.

Market Cap: $121.4B vs $236.1B

Size Category: Large Cap vs Mega Cap

A high score suggests the companies are in the same size category, facing similar challenges and opportunities in terms of market presence and financial flexibility.

valuation
A-

valuation

Compares valuation metrics to assess if the stocks are valued similarly by the market, indicating comparable investor expectations and perceived growth potential.

  • P/E Ratio: 0.00 vs 13.87
  • P/B Ratio: 7.38 vs 5.05
  • EV/EBITDA: 50.81 vs 10.01
  • Forward P/E: 8.76 vs 10.28
  • PEG Ratio: 1.35 vs 0.85

A high score indicates that the market values these companies similarly relative to their financials, suggesting comparable growth expectations and risk profiles.

sector
A+

sector

Compares the sector and industry classification of both companies, allowing for partial matches.

  • Sector: LIFE SCIENCES vs LIFE SCIENCES
  • Industry: PHARMACEUTICAL PREPARATIONS vs PHARMACEUTICAL PREPARATIONS

A high score indicates that the companies operate in similar business areas, facing comparable market conditions, regulatory environments, and industry trends. Partial matches are considered for more nuanced comparisons.

analyst ratings
A+

analyst ratings

Compares the consensus of analyst opinions on both stocks.

  • BMY Rating: Hold
  • MRK Rating: Buy

A high score suggests that analysts view both stocks similarly in terms of their future prospects and investment potential.

geo
A+

geo

Evaluates the geographical similarity of the companies based on country, currency, exchange, and address.

  • BMY Country: USA
  • MRK Country: USA
  • Currency: USD vs USD
  • Exchange: NYQ vs NYQ

A high score indicates that both companies operate in similar geographical markets, facing comparable economic conditions, regulations, and market dynamics.

volatility
A+

volatility

Compares price volatility and risk profiles, indicating similarity in market behavior, risk, and potential for price swings.

  • BMY Beta: 0.44 (Low)
  • MRK Beta: 0.36 (No Correlation)

A high score suggests both stocks have similar sensitivity to market movements, implying comparable risk levels and potential for both gains and losses.

business similarity
A+

business similarity

Assesses the similarity of the companies' business models, products, and services.

This score is based on an analysis of the companies' business descriptions, major products, and revenue streams.

A high score indicates that the companies have similar core businesses, target markets, and revenue generation strategies.

momentum
A+

momentum

Compares recent price momentum, showing similarity in short-term market performance and investor sentiment.

  • BMY Price vs 200-day MA: 116.77%
  • MRK Price vs 200-day MA: 84.90%

A high score indicates both stocks are experiencing similar price trends relative to their recent history, suggesting comparable market enthusiasm or concern.

dividend
A+

dividend

Compares dividend policies, showing similarity in shareholder return strategies and income potential for investors.

  • BMY Dividend Yield: 4%
  • MRK Dividend Yield: 4%

A high score indicates similar approaches to returning capital to shareholders, suggesting comparable appeal to income-focused investors.

Select Mutual Comparables:

Trailing P/E
N/A
Forward P/E
8.76
PEG Ratio
1.35
Price/Book
7.38
EV/EBITDA
50.81
EV/Revenue
3.33

Income Statement

Revenue (TTM)
$48.3B
Gross Profit (TTM)
$36.4B
EBITDA
$19.4B

Financial Ratios

Profit Margin
-19%
Operating Margin (TTM)
23%
Gross Profit Margin
N/A
EBITDA Margin
N/A
ROE (TTM)
-39%
ROA (TTM)
7%

Growth

Quarterly Revenue Growth (YoY)
8%
Quarterly Earnings Growth (YoY)
-96%
52-Week Range
$38.18
$59.81
$61.10
50-Day Moving Average
$57.38
Price vs. 50-Day MA
4.23%
200-Day Moving Average
$51.22
Price vs. 200-Day MA
16.77%
Analyst Ratings Distribution
0
1
17
4
4
Strong Sell Strong Buy
Median Price Target
$61.24
Price to Target
98%

AbbVie Inc.

ABBV - NYQ
View ABBV's Comps
A
TaxGhost's "TG Grade" is calculated from 100+ datapoints including fundamental metrics, factors, country, correlation, sub-sector, and more.
Life Sciences
Pharmaceutical Preparations
Market Cap: $378.3B
Volume: 6.8M (Moderate)
Beta: 0.60 (Low)
Dividend Yield: 3%
Strong Momentum
Fair Value
Good Quality
Mega Cap

AbbVie is an American publicly traded biopharmaceutical company founded in 2013. It originated as a spin-off of Abbott Laboratories.

Compare
Valuation
Financials
Momentum
Ratings

AbbVie Inc. is a biopharmaceutical company that specializes in immunology and oncology, positioning it as a comparable entity with similar market dynamics and challenges in the pharmaceutical landscape.

correlation
B

correlation

Measures how closely the two stocks' prices move together over time. A high correlation suggests similar market reactions and investor sentiment.

Pearson Correlation: 32%

R-squared: 10%

This indicates a weak positive relationship between the price movements of these stocks.

network
A+

network

Evaluates the overlap in business networks, partnerships, and industry relationships, indicating similarity in market positioning and competitive landscape.

  • Common comparables: 6
  • ABBV in MRK's comparables: Yes
  • MRK in ABBV's comparables: No

A high score suggests the companies are often compared to each other and share many industry peers, indicating similar competitive environments and market perceptions.

financials
A

financials

Compares key financial metrics to assess operational similarity and financial health.

  • Revenue Growth: 6% vs 7%
  • Profit Margin: 8% vs 27%
  • ROE: 62% vs 41%
  • Operating Margin: 33% vs 34%
  • Revenue (TTM): $56.3B vs $64.2B

A high score indicates similar financial performance, efficiency, and growth trajectories, suggesting comparable business models and market positions.

size
A+

size

Evaluates similarity in market capitalization, which can indicate comparable market influence, investor interest, and resource availability.

Market Cap: $378.3B vs $236.1B

Size Category: Mega Cap vs Mega Cap

A high score suggests the companies are in the same size category, facing similar challenges and opportunities in terms of market presence and financial flexibility.

valuation
C

valuation

Compares valuation metrics to assess if the stocks are valued similarly by the market, indicating comparable investor expectations and perceived growth potential.

  • P/E Ratio: 89.29 vs 13.87
  • P/B Ratio: 113.77 vs 5.05
  • EV/EBITDA: 29.50 vs 10.01
  • Forward P/E: 17.48 vs 10.28
  • PEG Ratio: 0.45 vs 0.85

A high score indicates that the market values these companies similarly relative to their financials, suggesting comparable growth expectations and risk profiles.

sector
A+

sector

Compares the sector and industry classification of both companies, allowing for partial matches.

  • Sector: LIFE SCIENCES vs LIFE SCIENCES
  • Industry: PHARMACEUTICAL PREPARATIONS vs PHARMACEUTICAL PREPARATIONS

A high score indicates that the companies operate in similar business areas, facing comparable market conditions, regulatory environments, and industry trends. Partial matches are considered for more nuanced comparisons.

analyst ratings
A+

analyst ratings

Compares the consensus of analyst opinions on both stocks.

  • ABBV Rating: Buy
  • MRK Rating: Buy

A high score suggests that analysts view both stocks similarly in terms of their future prospects and investment potential.

geo
A+

geo

Evaluates the geographical similarity of the companies based on country, currency, exchange, and address.

  • ABBV Country: USA
  • MRK Country: USA
  • Currency: USD vs USD
  • Exchange: NYQ vs NYQ

A high score indicates that both companies operate in similar geographical markets, facing comparable economic conditions, regulations, and market dynamics.

volatility
A-

volatility

Compares price volatility and risk profiles, indicating similarity in market behavior, risk, and potential for price swings.

  • ABBV Beta: 0.60 (Low)
  • MRK Beta: 0.36 (No Correlation)

A high score suggests both stocks have similar sensitivity to market movements, implying comparable risk levels and potential for both gains and losses.

business similarity
A-

business similarity

Assesses the similarity of the companies' business models, products, and services.

This score is based on an analysis of the companies' business descriptions, major products, and revenue streams.

A high score indicates that the companies have similar core businesses, target markets, and revenue generation strategies.

momentum
A+

momentum

Compares recent price momentum, showing similarity in short-term market performance and investor sentiment.

  • ABBV Price vs 200-day MA: 116.93%
  • MRK Price vs 200-day MA: 84.90%

A high score indicates both stocks are experiencing similar price trends relative to their recent history, suggesting comparable market enthusiasm or concern.

dividend
A+

dividend

Compares dividend policies, showing similarity in shareholder return strategies and income potential for investors.

  • ABBV Dividend Yield: 3%
  • MRK Dividend Yield: 4%

A high score indicates similar approaches to returning capital to shareholders, suggesting comparable appeal to income-focused investors.

Select Mutual Comparables:

Trailing P/E
89.29
Forward P/E
17.48
PEG Ratio
0.45
Price/Book
113.77
EV/EBITDA
29.50
EV/Revenue
7.81

Income Statement

Revenue (TTM)
$56.3B
Gross Profit (TTM)
$39.6B
EBITDA
$26.2B

Financial Ratios

Profit Margin
8%
Operating Margin (TTM)
33%
Gross Profit Margin
N/A
EBITDA Margin
N/A
ROE (TTM)
62%
ROA (TTM)
8%

Growth

Quarterly Revenue Growth (YoY)
6%
Quarterly Earnings Growth (YoY)
-12%
52-Week Range
$149.56
$214.29
$215.66
50-Day Moving Average
$187.52
Price vs. 50-Day MA
14.28%
200-Day Moving Average
$183.26
Price vs. 200-Day MA
16.93%
Analyst Ratings Distribution
0
0
10
11
6
Strong Sell Strong Buy
Median Price Target
$209.13
Price to Target
102%
Toggle between similar stocks and ETFs for comparison.

Loading comparable stocks ...

Pfizer Inc.

PFE - NYQ
A+
$25.87 +0.12 (0.47%)
Life Sciences
Pharmaceutical Preparations
Market Cap: $146.6B
Volume: 24.6M (High)
Beta: 0.54 (Low)
Dividend Yield: 7%
Weak Momentum
Value
Average Quality
Large Cap
$25.87
$23.71 $30.55

Pfizer Inc. is an American multinational pharmaceutical and biotechnology corporation headquartered on 42nd Street in Manhattan, New York City. The name of the company commemorates its co-founder, Cha...

Pfizer Inc. is an American multinational pharmaceutical and biotechnology corporation headquartered on 42nd Street in Manhattan, New York City. The name of the company commemorates its co-founder, Charles Pfizer (1824-1906). Pfizer develops and produces medicines and vaccines for immunology, oncology, cardiology, endocrinology, and neurology. The company has several blockbuster drugs or products that each generate more than 1 billion USD in annual revenues.

Johnson & Johnson

JNJ - NYQ
A+
$165.02 +1.29 (0.79%)
Life Sciences
Pharmaceutical Preparations
Market Cap: $397.3B
Volume: 12.0M (High)
Beta: 0.51 (Low)
Dividend Yield: 3%
Neutral Momentum
Fair Value
Average Quality
Mega Cap
$165.02
$138.68 $166.43

Johnson & Johnson (J&J) is an American multinational corporation founded in 1886 that develops medical devices, pharmaceuticals, and consumer packaged goods. Its common stock is a component of the Dow...

Johnson & Johnson (J&J) is an American multinational corporation founded in 1886 that develops medical devices, pharmaceuticals, and consumer packaged goods. Its common stock is a component of the Dow Jones Industrial Average and the company is ranked No. 36 on the 2021 Fortune 500 list of the largest United States corporations by total revenue. Johnson & Johnson is one of the world's most valuable companies, and is one of only two U.S.-based companies that has a prime credit rating of AAA, higher than that of the United States government.

GSK plc

GSK - NYQ
A
$40.05 +0.75 (1.91%)
Life Sciences
Pharmaceutical Preparations
Market Cap: $81.6B
Volume: 8.1M (Moderate)
Beta: 0.29 (No Correlation)
Dividend Yield: 4%
Neutral Momentum
Value
Good Quality
Large Cap
$40.05
$31.37 $44.37

GlaxoSmithKline plc is dedicated to the creation, discovery, development, manufacture and marketing of pharmaceuticals, vaccines, over-the-counter drugs and health-related consumer products in the UK,...

GlaxoSmithKline plc is dedicated to the creation, discovery, development, manufacture and marketing of pharmaceuticals, vaccines, over-the-counter drugs and health-related consumer products in the UK, US and internationally. The company is headquartered in Brentford, the United Kingdom.

Bristol-Myers Squibb Company

BMY - NYQ
A
$59.81 -0.01 (-0.02%)
Life Sciences
Pharmaceutical Preparations
Market Cap: $121.4B
Volume: 6.3M (Moderate)
Beta: 0.44 (Low)
Dividend Yield: 4%
Neutral Momentum
Fair Value
Average Quality
Large Cap
$59.81
$38.18 $61.10

Bristol Myers Squibb (BMS) is an American multinational pharmaceutical company, headquartered in New York City. Bristol Myers Squibb manufactures prescription pharmaceuticals and biologics in several...

Bristol Myers Squibb (BMS) is an American multinational pharmaceutical company, headquartered in New York City. Bristol Myers Squibb manufactures prescription pharmaceuticals and biologics in several therapeutic areas, including cancer, AIDS, cardiovascular disease, diabetes, hepatitis, rheumatoid arthritis and psychiatric disorders.

AbbVie Inc.

ABBV - NYQ
A
$214.29 +3.54 (1.68%)
Life Sciences
Pharmaceutical Preparations
Market Cap: $378.3B
Volume: 6.8M (Moderate)
Beta: 0.60 (Low)
Dividend Yield: 3%
Strong Momentum
Fair Value
Good Quality
Mega Cap
$214.29
$149.56 $215.66

AbbVie is an American publicly traded biopharmaceutical company founded in 2013. It originated as a spin-off of Abbott Laboratories.

AbbVie is an American publicly traded biopharmaceutical company founded in 2013. It originated as a spin-off of Abbott Laboratories.